Tigermed Plans Governance Revamp With New Vice Chairman and Expanded Co-President Roles

Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has shared an update.

Hangzhou Tigermed Consulting Co., Ltd. has proposed amendments to its articles of association to add the role of vice chairman to its seven-member board and to increase the number of co-presidents from one to two, reflecting evolving operational and development needs. These governance changes, which leave other provisions unchanged, aim to refine the company’s leadership structure and will take effect only after approval by shareholders at a forthcoming general meeting, with subsequent regulatory filings to be handled by management under board authorization.

The company will issue a circular detailing the proposed amendments and the notice of the general meeting on the HKEXnews platform and its own website, as well as provide printed copies to shareholders who request them. By formalizing an expanded executive lineup and clarifying its board hierarchy, Tigermed appears to be positioning its management framework to better support growth and oversight in a competitive contract research sector.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research organization serving the pharmaceutical and biotech industries. The company provides clinical research and related consulting services, supporting drug development and regulatory processes for clients in domestic and international markets.

YTD Price Performance: -2.63%

Average Trading Volume: 2,034,252

Technical Sentiment Signal: Sell

Current Market Cap: HK$46.16B

For an in-depth examination of 3347 stock, go to TipRanks’ Overview page.